Mass Tort brief
Israeli Generic Giants Face Mounting U.S. Mass Tort Exposure
Appellate reversals, price-fixing settlements, and expanding medical device dockets fuel long-term liabilities for Teva and Taro.
Mass Tort
Glenmark's settlement and agreement to cooperate leaves Teva increasingly isolated — forcing the Israeli manufacturer to choose between an expensive settlement or a high-stakes federal trial.
BackgroundState attorneys general frequently collaborate on massive antitrust investigations into corporate price manipulation. In the generic pricing litigation, state complaints allege a multi-billion dollar conspiracy involving dozens of generic pharmaceutical manufacturers.
- Under the deal, Glenmark agreed to implement internal compliance reforms and cooperate in the ongoing multidistrict litigation currently pending in Connecticut federal court.
- State complaints explicitly designate Teva's U.S. subsidiary as the central ringleader of the price-fixing conspiracy involving 116 generic medications.
- As smaller co-defendants settle and agree to cooperate, Teva faces rising pressure as it heads toward a high-stakes federal trial in Hartford.
Mass Tort
Teva's expanding ParaGard contraceptive litigation in Georgia guarantees years of costly, unresolved medical device liabilities — maintaining downward pressure on its long-term financial recovery.
BackgroundMultidistrict litigation consolidates numerous individual lawsuits from across the United States into a single federal court to coordinate pretrial discovery. The ParaGard lawsuits allege that the copper contraceptive device is prone to breaking during removal and causing severe internal injuries.
- The new filings, including Hays v. Teva, allege manufacturing defects that require invasive surgical procedures to retrieve the broken pieces, raising potential medical damages.
- Judge Leigh Martin May continues to stay generic defendants' responsive pleading obligations, aiming to prevent administrative gridlock as the docket continues to expand.
- The expansion of these U.S. liabilities is closely watched on the Tel Aviv Stock Exchange, where institutional investors are assessing the drugmaker's long-term balance sheet.
Mass Tort
By reviving over 500 generic Tylenol lawsuits, the appellate court restored the plaintiffs' legal leverage — exposing Teva and other generic manufacturers to potentially massive damages.
BackgroundMultidistrict litigation was halted in 2024 when a federal judge excluded the plaintiffs' scientific and epidemiological experts under strict evidentiary rules. Under these rules, judges act as gatekeepers to determine if scientific testimony is sufficiently reliable for a jury to hear.
- The appellate panel ruled that the district court applied an overly rigid standard when excluding the epidemiological experts, sending the massive docket back to the lower court.
- Teva's primary U.S. subsidiary is a key generic defendant in these prenatal failure-to-warn lawsuits, directly exposing the parent company to high-stakes legal liabilities.
- While the decision does not prove acetaminophen causes developmental disorders, it forces the generic manufacturers to face expensive document discovery and potential jury trials.
Mass Tort
Taro's $200M price-fixing settlement phase begins — resolving a massive, decade-long liability that has long weighed on the Haifa-based generic manufacturer's balance sheet.
BackgroundAntitrust class actions in the pharmaceutical sector typically allege that generic drug manufacturers colluded to artificially inflate prices and allocate market share. Treble damages under U.S. antitrust laws can easily threaten the financial survival of mid-sized generic manufacturers.
- Consumers and third-party health plans who paid for affected generic drugs between 2009 and 2019 have until November 9, 2026, to submit proof-of-payment claims.
- The administrative activation of this settlement represents a major resolution milestone for Taro, which operates its global headquarters and primary manufacturing from Haifa, Israel.
- The payout resolves a decade-long regulatory threat, allowing the Israeli pharmaceutical company to remove a major legal liability from its balance sheet.
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.